DOCSLIB.ORG

Right Now, Researchers, Fundraisers, Doctors, Nurses, Patients, Volunteers, Campaigners, Supporters Are Beating Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Right Now, Researchers, Fundraisers, Doctors, Nurses, Patients, Volunteers, Campaigners, Supporters Are Beating Cancer RIGHT NOW, RESEARCHERS, FUNDRAISERS, DOCTORS, NURSES, PATIENTS, VOLUNTEERS, CAMPAIGNERS, SUPPORTERS ARE BEATING CANCER OUR ANNUAL REVIEW 2016/17 THANKS TO YOU WE ARE BEATING CANCER Discover more of our stories at cruk.org.uk/blog Cancer Research UK’s vision is to bring forward the day when all cancers are cured. Our ambition is to see 3 in 4 people surviving cancer for 10 years or more by 2034. We’re working to prevent cancer, diagnose it earlier, develop new treatments and optimise existing treatments to make them more effective. CONTENTS INTRODUCTION DIAGNOSING CANCER EARLIER MAKING CANCER TREATMENT 02 A message from our 26 Working to improve early MORE EFFECTIVE Chairman and CEO diagnosis services 42 Discovering a missing piece 03 A message from one 28 Can we diagnose cancer of the cancer puzzle of our scientists in GP surgeries? 44 Remembering my brother Mark 04 About us 30 Helping to make sure cancer 46 Taking a new approach to 05 Our strategy is spotted early tackling bladder cancer 06 Evaluating our progress 48 Taking part in life-changing trials DEVELOPING NEW CANCER TREATMENTS GROUNDBREAKING THANKS TO YOU MOMENTS IN 2016/17 34 Tackling hard-to-treat cancers 52 “Thank you to everyone who supports Cancer Research UK” 10 Grand Challenge: Sparking a 36 Helping change the way we revolution in cancer research treat pancreatic cancer 54 How we raised and spent our money 12 Making vital discoveries at 38 Improving treatment for children the Francis Crick Institute with cancer 57 Our year in numbers 58 A timeline of our 2016/17 PREVENTING CANCER highlights 18 Cutting obesity down to size 60 For you, because of you, thanks to you 20 M aking healthier choices 64 Help us beat cancer sooner 22 C ould exercise prevent bowel cancer coming back? OUR ANNUAL REVIEW | 01 PREVENT Preventing cancer Find out more: page 16 Diagnosing cancer earlier DIAGNOSE Find out more: page 24 Developing new cancer treatments TREAT Find out more: page 32 Making cancer treatment OPTIMISE more effective OPTIMISEOPTIMISE Find out more: page 40 WE ARE BEATING CANCER WE ARE BEATING ANNUAL REPORT AND ACCOUNTS 2016/17 CANCER WE ARE BEATING CANCER RIGHT NOW, OUR ANNUAL REVIEW 2016/17 RESEARCHERS, FUNDRAISERS, 2016/17 DOCTORS, NURSES, PATIENTS, VOLUNTEERS, RIGHT NOW, RESEARCHERS, CAMPAIGNERS, FUNDRAISERS, DOCTORS, NURSES, SUPPORTERS PATIENTS, VOLUNTEERS, CAMPAIGNERS, ARE BEATING SUPPORTERS ARE BEATING CANCER CANCER ANNUAL REPORT OUR AND ACCOUNTS OUR ANNUAL REVIEW HIGHLIGHTS 2016/17 2016/17 2016/17 Look out for this icon Find the Annual Review, Annual Report and Accounts throughout the Annual Review and Highlights online at cruk.org/our-year to discover more online 02 | INTRODUCTION SIR HARPAL KUMAR AND PROFESSOR SIR LESZEK BORYSIEWICZ THANKS TO YOU WE’RE BEATING CANCER RESEARCH TO BENEFIT PATIENTS HEALTHY LIFESTYLES Among the exciting research projects Tackling rising obesity rates is an urgent we supported this year were the first priority, as we estimate obesity will Grand Challenge awards. We believe cause 670,000 new cancer cases in the the four winning projects will next 20 years. We are addressing this revolutionise our understanding issue through research, campaigning of cancer (see page 10). and awareness raising (see page 18). The TRACERx study is looking at Our tobacco campaigning saw the evolution of cancer by following major successes this year, including lung cancer patients throughout the roll‑out of plain packaging and their treatment. As part of the study, smoking rates continuing to fall. researchers developed a blood test But there is more to do. Our ‘Don’t Quit and have published findings showing on Us’ campaign aims to protect vital that it could detect relapse in patients Stop Smoking Services, which are at who have had surgery up to a year risk from government budget cuts. before standard testing. WORKING TOGETHER INVESTING IN THE FUTURE TO BEAT CANCER We are also investing in the future None of our work would be possible of research, ensuring systems and without our supporters. We strive to resources are in place for researchers make sure that your donations are spent to continue their important work in in the best way. And we involve people years to come. affected by cancer to help shape our work. Alongside many other projects This year saw the opening of the this year, our patient representatives Francis Crick Institute, which we played a vital role in the development One in two people born in co‑funded (see page 12). We also of the Grand Challenge awards. the UK since 1960 will be announced our largest ever investment diagnosed with cancer in in our network of Centres – hubs which It has been an exciting year, and we their lifetime. So it is vital that bring together world‑class expertise want to thank all our amazing supporters, in research and medicine, to help get volunteers, scientists, doctors, nurses we work together to beat life‑saving treatments to patients faster. and partners. Every one of you is the disease. Everyone, from helping to beat cancer sooner. researchers, to patients and We have also had challenges. A fire at our Manchester Institute, in which supporters, can help us achieve thankfully no one was hurt, significantly our goal of seeing 3 in 4 people damaged research facilities. It was surviving cancer for 10 years heartening to see our staff and or more by 2034. supporters rally round, and the Sir Harpal Kumar generous donations of the public will help to get the Institute back on its feet. Chief Executive Professor Sir Leszek Borysiewicz Chairman 24 May 2017 OUR ANNUAL REVIEW | 03 DR UDAI BANERJI BRINGING BETTER DRUGS TO PATIENTS I’M MOTIVATED BY PATIENTS YOU MAKE MY WORK POSSIBLE The patients volunteering for our Cancer Research UK’s support meant trials often have advanced cancers I could design and conduct a national and have already had several different early‑phase clinical trial combining treatments. It is a privilege to work with a new drug called vistusertib with patients who, at a difficult time in their a known cancer drug, paclitaxel. lives, enrol in trials to help science, The findings of this study led to this medicine and the next generation of combination being further evaluated cancer patients. My motivation is to in treating ovarian cancer. help patients by evaluating innovative It is only because of Cancer medicines developed by Cancer Research UK’s many generous Research UK scientists in early supporters that researchers like me clinical trials. I’m a Cancer Research UK can do our work. Thank you to clinician scientist at The My lab focuses on making sure that a everyone who has donated time or cancer drug acts in the way we intend money to this important cause. You’re Institute of Cancer Research, and ‘does what it says on the tin’. making these advances possible. London. I work in the early This research helps us tailor doses stages of drug development, of the drugs. Funding from Cancer where new drugs are given to Research UK also allows me to conduct patients for the first time to see experiments to find new combinations of cancer drugs that are needed to how they work in the body. Dr Udai Banerji fight the disease. Cancer Research UK clinician scientist SUPPORTING THE ENTIRE PROCESS 24 May 2017 Cancer Research UK supports many different stages of cancer drug development, funding researchers, labs and equipment. They also train, fund and empower talented scientists, nurses, data managers, clinical trial coordinators and medical staff, who are all critical to cancer drug development. PARTNERSHIPS HELP US MAKE A DIFFERENCE It’s so important that different parts of the health system, including drug companies, the NHS and charities, work together to develop new treatments faster. That’s why it’s great that Cancer Research UK is working with partners like the Departments of Health to fund Experimental Cancer Medicine Centres. Initiatives like this will also help make sure research findings are developed into effective cancer treatments as soon as possible. 04 | INTRODUCTION ABOUT US Cancer Research UK is the world’s largest cancer charity dedicated to saving lives through research. Our vision is to bring forward the day when all cancers are cured, from the most common types to those that affect just a few people. One in two people born in the UK be done. While survival for some after 1960 will be diagnosed with cancers has improved dramatically, cancer at some point in their lives. others, like brain tumours, and lung, Right now, half of the people pancreatic and oesophageal cancers, diagnosed with cancer will survive are still very hard to treat. We need to their disease for at least 10 years. change that, so we’ve increased the amount we’re spending on these Our ambition is to accelerate cancers as part of our research strategy. 1970s progress and see 3 in 4 people surviving cancer for 10 years or Our research has shown that more more by 2034. than four in ten cancers in the UK are preventable, and we are working to Every day, scientists, doctors and In the 1970s, ensure everything possible is being nurses are working to save more lives. 1 in 4 people done to reduce the number of people They’re preventing more cancers, diagnosed with who develop the disease. cancer in the UK diagnosing the disease earlier, survived for 10 and developing new treatments. None of our life‑saving work would years or more Our work to engage and inform be possible without the strength of patients, policy makers and the public our fundraising and our outstanding is helping to ensure our research people – our supporters, volunteers, is making a real difference.
Load more

Recommended publications
  • Written Evidence UK Centre for Medical
    Science & Technology Committee: Written evidence UK Centre for Medical Research & Innovation (UKCMRI) This volume contains the written evidence accepted by the Science & Technology Committee for the UK Centre for Medical Research & Innovation (UKCMRI) inquiry. UKCMRI Author UKCMRI Author 00 BIS 17 Camden Green Party 01 Faculty of Pharmaceutical Medicine 18 Councillor Roger Robinson, St Pancras and Somers Town Ward 02 The Academy of Medical Sciences 20 John Mason 03 Director, Medical Research Council 21 T Morgan National Institute for Medical Research 04 UKCMRI Limited 22 Frankie Biney 04a Supplementary 04b Further supplementary 04c Further supplementary 05 Robert Henderson 23 Rt. Hon. Frank Dobson MP 05a Supplementary 06 Medical Research Council’s National Trade Union Side 07 Mireille Burton 08 King’s College London 09 Joint submission: Cancer Research UK, MRC, UCL, and Wellcome Trust 09a Supplementary (MRC) 09b Further supplementary (MRC) 10 Isabel Vasseur 11 St Pancras and Somers Town Planning Action 11a Supplementary 12 Imperial College London 13 The Public & Commercial Services Union 14 Action for our Planet 15 GlaxoSmithKline R&D 16 Professor G G Dodson 16a Supplementary 16b Further supplementary As at 20 April 2011 Written evidence submitted by the Department for Business, Innovation & Skills (BIS) (UKCMRI 00) The UK Centre for Medical Research and Innovation (UKCMRI) will be a world-class centre for biomedical research, located in the London Borough of Camden. UKCMRI will be an independent institute funded by the Medical Research Council, Cancer Research UK, the Wellcome Trust and University College London. The funding partners, and separately UKCMRI, will also be submitting a memorandum to the Select Committee.
    [Show full text]
  • [email protected] FST Journal Publishes Summaries of All the Talks Given at Its Meetings
    journal The Journal of The Foundation for Science and Technology fstVolume 22 Number 2 March 2018 www.foundation.org.uk Editorial Sir David Cannadine: The role of the Academies in providing independent advice to Government An industrial strategy for the UK Lord Hennessy: Searching for a strategy that makes a difference Lord Heseltine: Establishing a strategy for the whole economy Lord Willetts: A tension at the heart of Government activity A business strategy for Scotland Professor Iain Gray: Translating research excellence into economic benefit Nora Senior: Plugging gaps in performance Dame Susan Rice: An ecosystem for business Paul Wheelhouse: Driving innovation Meeting air quality targets Dr Stephen Bryce: The energy emissions challenge Professor Frank Kelly: The health consequences of air pollution Diagnosing cancer earlier Sir Harpal Kumar: Early diagnosis has the potential to transform patient outcomes Dr Clare Turnbull: Using genetics to combat cancer The rise of machine learning Dr Mike Lynch: An opportunity or a threat to society? Dr Claire Craig: Giving society the confidence to embrace opportunities Amir Saffari: The potential to augment human efforts Dame Wendy Hall: The opportunities for the UK Comment Norman Lamb: The future of social care Obituary The Rt Hon Sir Brian Neill COUNCIL AND TRUSTEES COUNCIL CHIEF EXECUTIVE Chair Dr Dougal Goodman OBE FREng The Earl of Selborne* GBE FRS Deputy Chairs The Baroness O’Neill of Bengarve* CH CBE FBA FRS FMedSci Dr Mike Lynch* OBE FRS FREng DL President, The Royal Society Professor
    [Show full text]
  • Trustees' Annual Report and Financial Statements 31 March 2016
    THE FRANCIS CRICK INSTITUTE LIMITED A COMPANY LIMITED BY SHARES TRUSTEES’ ANNUAL REPORT AND FINANCIAL STATEMENTS 31 MARCH 2016 Charity registration number: 1140062 Company registration number: 6885462 The Francis Crick Institute Accounts 2016 CONTENTS INSIDE THIS REPORT Trustees’ report (incorporating the Strategic report and Directors’ report) 1 Independent auditor’s report 12 Consolidated statement of financial activities 13 Balance sheets 14 Cash flow statements 15 Notes to the financial statements 16 1 TRUSTEES’ REPORT (INCORPORATING THE STRATEGIC REPORT AND DIRECTORS’ REPORT) The trustees present their annual directors’ report together with the consolidated financial statements for the charity and its subsidiary (together, ‘the Group’) for the year ended 31 March 2016, which are prepared to meet the requirements for a directors’ report and financial statements for Companies Act purposes. The financial statements comply with the Charities Act 2011, the Companies Act 2006, and the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK (FRS102) effective 1 January 2015 (Charity SORP). The trustees’ report includes the additional content required of larger charities. REFERENCE AND ADMINISTRATIVE DETAILS The Francis Crick Institute Limited (‘the charity’, ‘the Institute’ or ‘the Crick) is registered with the Charity Commission, charity number 1140062. The charity has operated and continues to operate under the name of the Francis Crick
    [Show full text]
  • 2011 Gairdner Foundation Annual Report
    2011 GAIRDNER FOUNDATION ANNUAL REPORT May 30, 2012 TABLE OF CONTENTS TABLE OF CONTENTS ...................................................................................................................................... 2 HISTORY OF THE GAIRDNER FOUNDATION .............................................................................................. 3 MISSION,VISION ................................................................................................................................................ 4 GOALS .................................................................................................................................................................. 5 MESSAGE FROM THE CHAIR .......................................................................................................................... 6 MESSAGE FROM THE PRESIDENT/SCIENTIFIC DIRECTOR ..................................................................... 7 2011 YEAR IN REVIEW ..................................................................................................................................... 8 REPORT ON 2011 OBJECTIVES ..................................................................................................................... 12 THE YEAR AHEAD: OBJECTIVES FOR 2012 ............................................................................................... 13 2011 SPONSORS ................................................................................................................................................ 14 GOVERNANCE
    [Show full text]
  • UKRI Explainer
    UK Research and Innovation (UKRI) What is UKRI? UK Research and Innovation (UKRI) was established by the UKRI delivers the majority of public funding for research Higher Education and Research Act 2017 and was launched and innovation in the UK. It will play a central role in in April 2018. The purpose of UKRI is to create a strong, realising the UK Government’s ambition of 2.4% of gross agile and joined up funder of research and innovation for domestic product (GDP) investment in research and the UK. UKRI brings together the seven Research Councils, development (R&D) by 2027. This explainer summarises Innovate UK and Research England (formally the Higher UKRI’s structure, governance and operation to support Education Funding Council for England (HEFCE)). UKRI and discussion over how this funding is distributed. its constituent Councils published their first Delivery Plans in June 20191. FIGURE 1 Who makes up UKRI? UK Research and Innovation (UKRI) Engineering UKRI is made up of nine Councils: seven Research Councils, Innovate UK Economic and Physical and Social and Research England. Sciences Research Research Council Research Councils Council (ESRC) (EPSRC) The seven Research Councils, divided by scientific discipline, support Biotechnology and Biological Medical excellent research by providing grant funding, access to excellent research Sciences Research facilities and investing in infrastructure and institutions. Research Council Council (MRC) Innovate UK (BBSRC) The UK’s innovation agency, works with companies to de-risk, enable and support innovation, including through providing innovation grants and UK Research and Science and Arts and investing in Catapult centres. Technology Innovation (UKRI) Humanities Facilities Research Research England Council Council Research England supports English Higher Education providers to (STFC) (AHRC) deliver funding for research and knowledge exchange formerly performed by HEFCE.
    [Show full text]
  • The Molecular Basis of Mecp2 Function in the Brain
    Edinburgh Research Explorer The molecular basis of MeCP2 function in the brain Citation for published version: Tillotson, R & Bird, A 2020, 'The molecular basis of MeCP2 function in the brain', Journal of Molecular Biology, vol. 432, no. 6. https://doi.org/10.1016/j.jmb.2019.10.004 Digital Object Identifier (DOI): 10.1016/j.jmb.2019.10.004 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Journal of Molecular Biology General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 Review The Molecular Basis of MeCP2 Function in the Brain Rebekah Tillotson 1,2 and Adrian Bird 3 1 - Genetics and Genome Biology Program, The Hospital for Sick Children, The Peter Gilgan Centre for Research and Learning, Toronto, ON M5G 0A4, Canada 2 - Medical Research Council (MRC) Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DS, UK 3 - Wellcome Centre for Cell Biology, University of Edinburgh, The Michael Swann Building, King's Buildings, Max Born Crescent, Edinburgh, EH9 3BF, UK Correspondence to Adrian Bird: [email protected] https://doi.org/10.1016/j.jmb.2019.10.004 Edited by Tuncay Baubec Abstract MeCP2 is a reader of the DNA methylome that occupies a large proportion of the genome due to its high abundance and the frequency of its target sites.
    [Show full text]
  • Acknowledgment of Reviewers, 2015
    Acknowledgment of Reviewers, 2015 The PNAS editors would like to thank all the individuals who dedicated their considerable time and expertise to the journal by serving as reviewers in 2015. Their generous contribution is deeply appreciated. A Peter B. Adler Colin J. Akerman Eric E. Allen James Ammerman Duur K. Aanen Ralph Adolphs Joshua M. Akey Heather C. Allen David M. Amodio Adam R. Abate Ruedi Aebersold Anna Akhmanova Jim Allen Valentin Amrhein John T. Abatzoglou Hugo Aerts Hajime Akimoto Karen N. Allen Esther Amstad Jonathan Abbatt Hagit P. Affek Akin Akinc Michael F. Allen Ronald Amundson Allison Abbott Arash Afraz Shizuo Akira Paul M. Allen Weihua An Jeffrey Abbott Theodor Agapie Ozan Akkus Rosalind J. Allen Zhiqiang An Larry F. Abbott David A. Agard Ivona Aksentijevich Morten Erik Allentoft Laura Diaz Anadon Nicholas L. Abbott Sapan Agarwal Serap Aksoy Stefano Allesina Ganesh Srinivasan Anand Chaouki T. Abdallah Joel W. Ager III Yousef Al-Abed David B. Allison Cort Anastasio Omar Abdel-Wahab Ingi Agnarsson Ashraf Al-Amoudi Steven D. Allison Lefteris Jason Ikuro Abe Anurag A. Agrawal Eric E. Alani Julian M. Allwood Anastasopoulos Stephen Tobias Abedon Ashutosh Agrawal Balbino Alarcón Eric J. Alm Hossain Anawar Moshe Abeles Rakesh Agrawal Qais Al-Awqati Benjamin A. Alman Elissar Andari Asa Abeliovich Jon Ågren Joseph Albanesi Ingvild Almas William R. L. Anderegg John Aber Alan Agresti Francis Albarede Steven C. Almo John M. Anderies Clara Abraham Jeremy J. Agresti Umberto Albarella Douglas Almond Mark L. Andermann John Abraham Jay J. Ague Silas D. Alben Uri Alon Bogi Andersen Daniel A. Abrams Fernan Agüero Frank Alber José M.
    [Show full text]
  • DNA Methylation Patterns and Cancer
    restriction/modification system, which brought Werner Arber, Daniel Nathans and Hamilton Smith the 1978 Nobel Prize in Physiology or Medicine, and made restriction enzymes the primary tools of Charles Rodolphe Brupbacher Foundation molecular biology. Four decades have passed since then, but the role of 5-methylcytosine in eukaryotic DNA metabolism is still shrouded in mystery. We know that the sperm methylation pattern is largely The erased after fertilization and that methylation is gradually reintroduced Charles Rodolphe Brupbacher Prize during embryogenesis and differentiation, but the processes that for Cancer Research 2017 regulate the cell type- and tissue-specific methylation patterns remain is awarded to to be elucidated. We have also learned that DNA can be not only methylated, but also demethylated, and that aberrant methylation can lead to disease - including cancer. Again, how these processes are regulated remains to be discovered. However, we have learnt a great Sir Adrian Peter Bird, deal about 5-methylcytosine metabolism during the past three decades and much of our knowledge came from the laboratory of Adrian Bird. PhD Adrian spent his doctoral and postdoctoral time in Max Birnstiel’s for his contributions to our understanding laboratory, first in Edinburgh and then in Zurich, studying the amplification of ribosomal DNA in Xenopus laevis. In this organism, of the role of DNA methylation in genomic rDNA in somatic tissues is highly methylated, while the development and disease extrachromosomal amplicons are unmethylated. When he returned to Edinburgh to establish his own group, Adrian set out to study The President The President of the Foundation of the Scientific Advisory Board the methylation pattern of these loci using the newly-available methylation-sensitive restriction enzymes.
    [Show full text]
  • Ukcrc Agenda
    MINUTES UK CLINICAL RESEARCH COLLABORATION BOARD MEETING 11 October 2012 Minutes of the meeting held on 11 October 2012, Room 1, 13th Floor, MRC, One Kemble Street, London WC2B 4TS Present Members Professor Dame Sally Davies – Department of Health, England (Chair, DH) Sir John Savill – Medical Research Council (Deputy Chair/MRC) Bina Rawal – The Association of the British Pharmaceutical Industry (ABPI) Dr Helen Bodmer – Department for Business, Innovation and Skills (BIS) Sarah Buckland – INVOLVE Sharmila Nebhrajani - Association of Medical Research Charities (AMRC) Dr Russell Hamilton – Department of Health, England (DH) Harpal Kumar – Cancer Research UK (CRUK) Dr Richard Tiner – Academy of Medical Royal Colleges (AOMRC) Beth Thompson – Wellcome Trust Mike Stevens – Scottish Government Health Directorates Professor Bernie Hannigan – Health & Social Care R&D, Northern Ireland Steve Bates – BioIndustry Association (BIA) Michael Bowdery – National Institute for Social Care and Health Research, Welsh Assembly Government (NISCHR) John Hughes - Patient/Public Member Andrew Russell – Patient/Public Member Sir Ron Kerr – NHS Confederation Sir Nick Partridge – Patient/Public Member (Deputy Chair) David Adams – Academy of Medical Sciences (AMS) Professor Carole Longson – National Clinical Institute for Health and Clinical Excellence (NICE) Andy French - Medicines and Healthcare products Regulatory Agency (MHRA) Caroline Shaw - The Association of University Hospitals UK Paul Hubbard – Higher Education Funding Councils (HEFC) Professor Iain Cameron
    [Show full text]
  • Cancer Research Uk and Hsbc Join Forces in Usd25m Partnership to Build the Francis Crick Institute and Support the Scientific Le
    Thursday 22 October CANCER RESEARCH UK AND HSBC JOIN FORCES IN US$25M PARTNERSHIP TO BUILD THE FRANCIS CRICK INSTITUTE AND SUPPORT THE SCIENTIFIC LEADERS OF THE FUTURE Cancer Research UK today announced a partnership with HSBC to support the scientific leaders of tomorrow through a contribution of US$25 million towards the development of the Francis Crick Institute. The new state‐of‐the‐art biomedical research facility is currently being built in King’s Cross, in the heart of London. HSBC’s support is contributing to the cost of the construction of the Francis Crick Institute which is due to open in 2016. Cancer Research UK will receive US$5m per year from HSBC for the next five years (2015‐2019). The Francis Crick Institute will see more than 1,200 scientists, representing a variety of disciplines, collaborating to tackle the diseases that pose the greatest threat to humanity – cancer, heart disease, lung disease, infectious diseases such as HIV and malaria and many more. The collaboration between HSBC, Cancer Research UK and the Francis Crick Institute will be marked by 150 PhD students who will be provided with an opportunity to conduct vital research at the new institute. The young scientists will be selected from across the world for the PhD programme. Harpal Kumar, Chief Executive Officer at Cancer Research UK, said: “Cancer Research UK has a long history of working with HSBC, but this donation really is game‐changing for us. This extraordinarily generous gift will cement our commitment to investing in the highest quality science by helping us to support some of the best and most imaginative scientists in the world.” HSBC’s donation is part of a series of community investments being made globally to mark HSBC’s 150th anniversary.
    [Show full text]
  • Trial Please Esteemed Panel of Researchers
    The Biomedical and Life Sciences Collection • Regularly expanded, constantly updated • Already contains over 700 presentations • Growing monthly to over 1,000 talks “This is an outstanding Seminar style presentations collection. Alongside journals and books no self-respecting library in institutions hosting by leading world experts research in biomedicine and the life sciences should be without access to these talks.” When you want them, Professor Roger Kornberg, Nobel Laureate, Stanford University School of Medicine, USA as often as you want them “I commend Henry Stewart Talks for the novel and • For research scientists, graduate • Look and feel of face-to-face extremely useful complement to teaching and research.” students and the most committed seminars that preserve each Professor Sir Aaron Klug OM FRS, Nobel Laureate, The Medical senior undergraduates speaker’s personality and Research Council, University of approach Cambridge, UK • Talks specially commissioned “This collection of talks is a and organized into • A must have resource for all seminar fest; assembled by an extremely eminent group of comprehensive series that cover researchers in the biomedical editors, the world class speakers deliver insightful talks illustrated both the fundamentals and the and life sciences whether in with slides of the highest latest advances academic institutions or standards. Hundreds of hours of thought provoking presentations industry on biomedicine and life sciences. • Simple format – animated slides It is an impressive achievement!” with accompanying narration, Professor Herman Waldmann FRS, • Available online to view University of Oxford, UK synchronized for easy listening alone or with colleagues “Our staff here at GSK/Research Triangle Park wishes to convey its congratulations to your colleagues at Henry Stewart for this first-rate collection of talks from such an To access your free trial please esteemed panel of researchers.
    [Show full text]
  • The Birth of the Hong Kong Laureate Forum
    The Birth of the Hong Kong Laureate Forum On 26 September 2017, I attended the Shaw Prize Award Presentation Ceremony for the first time as Chief Executive of the Hong Kong Special Administrative Region. On that occasion, five distinguished scientists in Astronomy, Life Science and Medicine, and Mathematical Sciences were honoured. They are distinguished individuals who have achieved significant breakthrough in academic and scientific research and whose work has resulted in a positive and profound impact on mankind. As I was then drawing up a multi-pronged strategy to develop innovation and technology in Hong Kong, including the promotion of popular science education, I asked myself how we could bring together this pool of great scientific minds to help nurture the next generation of young scientists. This was the beginning of a year-long endeavour to create the Hong Kong Laureate Forum. I presented prizes at the Shaw Prize Award Presentation Ceremony 2017. From right are Laureate in Astronomy, Professor Simon DM White; Laureate in Life Science and Medicine, Professor Ronald D Vale; Laureates in Mathematical Sciences, Professor János Kollár and Professor Claire Voisin. Another Laureate in Life Science and Medicine, Professor Ian R Gibbons, did not attend the Ceremony. 1 Under the vision and generosity of the late Sir Run Run Shaw and with the unfailing support of his wife the late Lady Shaw, the Shaw Prize was established in 2002 to recognize advances and outstanding contributions in three disciplines, namely, Astronomy, Life Science and Medicine, and Mathematical Sciences. In less than two decades, the Shaw Prize has become a world-renowned award for the highest achievements in mankind.
    [Show full text]